Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to
placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of
the brain linked to visuospatial cognitive impairment in PD.